9901808-7 IPOS

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/00, 31/135, 31/13 — A2

(11) International Publication Number: WO 98/22100

(43) International Publication Date: 28 May 1998 (28.05.98)

(21) International Application Number: PCT/EP97/06408

(22) International Filing Date: 17 November 1997 (17.11.97)

(30) Priority Data:
(1) 9624038.7 19 November 1996 (19.11.96) GB

(71) Applicant *(for all designated States except US)*: NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH–4058 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: COTTENS, Sylvain [CH/CH]; In den Reben 12, CH–4108 Witterswil (CH). (2) HOF, Robert, Paul [CH/CH]; Im Huebacher 12, CH–4460 Gelterkinden (CH). (3) WENGER, Roland [CH/CH]; Grenzacherweg 45, CH–4125 Riehen (CH).

(74) Agent: ROTH, Bernhard, M.; Novartis AG, Patent– und Markenabteilung, Lichtstrasse 35, CH–4002 Basel (CH).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).


Published
Without international search report and to be republished upon receipt of that report.

1 PD
1 Appln.
3 Invs

(54) Title: NEW USE FOR 1,3–PROPANEDIOL DERIVATIVES

(57) Abstract

Use of a compound of formula (I) wherein R_1 is an optionally substituted straight– or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and each of R_2, R_3, R_4 and R_5, independently, is H or lower alkyl, in free form or in pharmaceutically acceptable salt form, in the prevention or treatment of chronic rejection in a recipient of organ or tissue allo– or xenotransplant, or of acute rejection in a xenograft transplant recipient.



(I)